The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. In the last decade, with increased emphasis in the last three years due to a world-wide pandemic, it has become a priority of NIAID to utilize new vaccine modalities, such as mRNA-LNP based vaccines, to combat emerging infectious diseases.  The Vaccine Production Program (VPP) is the development arm of the Vaccine Research Center (VRC). The mission of the VRC is to create and develop potentially lifesaving vaccines for HIV, Ebola, Zika, and other known pathogens and get these potentially lifesaving products into the clinic.  The Mass Spectrometry group within Analytical Development provides critical support for the Cell Culture, Cell Line, Downstream, and Formulations groups within the VPP.  Due the nature of our expertise, the Mass Spectrometry group also provides support for collaborators outside the VPP and outside NIH.  In Q12024, one of the VPP mass spectrometers reached its end of life and was decommissioned.  In order to maintain and improve current mass spectrometry capabilities and provide redundancy for high demand mass spectrometry workflows, a replacement mass spectrometer is needed.  Specifically, NIAID, VRC, VPP is seeking one (1) Brand Name or Equal Bruker Daltonics Mass Spectrometer Model timsTOF flex.